CN112300990A - Culture medium for in-vitro amplification and activation of gamma delta-T cells - Google Patents
Culture medium for in-vitro amplification and activation of gamma delta-T cells Download PDFInfo
- Publication number
- CN112300990A CN112300990A CN202010475488.9A CN202010475488A CN112300990A CN 112300990 A CN112300990 A CN 112300990A CN 202010475488 A CN202010475488 A CN 202010475488A CN 112300990 A CN112300990 A CN 112300990A
- Authority
- CN
- China
- Prior art keywords
- cells
- culture medium
- cell
- culture
- gamma delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title claims abstract description 51
- 239000001963 growth medium Substances 0.000 title claims abstract description 29
- 238000000338 in vitro Methods 0.000 title claims abstract description 12
- 230000004913 activation Effects 0.000 title claims abstract description 8
- 230000003321 amplification Effects 0.000 title abstract description 11
- 238000003199 nucleic acid amplification method Methods 0.000 title abstract description 11
- 210000001808 exosome Anatomy 0.000 claims abstract description 31
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 29
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 17
- 229960004276 zoledronic acid Drugs 0.000 claims description 17
- 239000002609 medium Substances 0.000 claims description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims description 11
- 102000000588 Interleukin-2 Human genes 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000012091 fetal bovine serum Substances 0.000 claims description 5
- 239000007640 basal medium Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 70
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 201000011510 cancer Diseases 0.000 abstract description 14
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000607 poisoning effect Effects 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 231100000572 poisoning Toxicity 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100039845 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Human genes 0.000 description 2
- 101710112841 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
- C12N2521/10—Sound, e.g. ultrasounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to a culture medium for in vitro amplification and activation of gamma delta-T cells, which comprises autologous dendritic cell exosomes, can effectively improve the cell amplification multiple and generate the gamma delta-T cells with high toxic activity to cancer cells.
Description
Technical Field
The invention relates to a culture medium for in vitro amplification and activation of gamma delta-T cells.
Background
Immune cell therapy is a treatment mode in which the immune cells of a patient are proliferated and activated in vitro and then returned to the body. At present, immune cell therapy is gradually applied to cancer therapy, and the key point of success is to understand the characteristics and functions of various immune cells and select the most suitable immune cell types, such as NK cells, T cells and the like, according to the conditions and gene characteristics of cancer patients.
T cells in the human immune system are largely divided into two major classes, Alpha-Beta T cells and Gamma-Delta T (γ. Delta. -T) cells. The gamma delta-T cells are present in peripheral blood in an amount of only 1% to 5% of all T cells in peripheral blood. It distinguishes normal from abnormal cells by recognizing isopentenyl pyrophosphate (IPP) molecules on the cell surface. IPP is an intermediate product of cellular metabolism and its production in cancer cells is increased, especially when p53 gene of cancer cells is mutated. The γ δ -T cells recognizing IPP proliferate and activate and enhance the force to attack tumor cells, which is a special function of γ δ -T cells, which can find and attack cancer cells if other immune cells do not detect cancer cell markers. In general, abnormal cells will possess molecules that are different from other normal cells, and γ δ -T cells will recognize and attack these as cancer cell markers. In addition to IPP molecules, γ δ -T cells can also be identified by markers such as MIC A/b, HMB-PP, intercellular adhesion molecule-1, CD166, etc. Thus, γ δ -T cells can recognize and kill a variety of cancer cells.
One important feature of γ δ -T cells is that they do not require HLA in identifying abnormal cells and are therefore independent of the individual's HLA type. This feature allows γ δ -T cells to be used in any human without producing graft-versus-host disease (GVHD). Many of the clinical applications of cell therapy in humans, which have been carried out in the united states, europe and japan, are currently carried out using γ δ -T cells, and these clinical applications have confirmed that the use of γ δ -T cells is safe and safe.
Since γ δ -T cells are scarce in blood and their proliferative capacity varies from person to person, the challenge of cell therapy with γ δ -T cells is whether it is possible to expand and activate γ δ -T cells in vitro in large quantities and rapidly. In recent years, the use of Zoledronic acid (Zoledronic acid) has been found to proliferate γ δ -T cells in large quantities, and its technology has also been established. In addition to the use of zoledronic acid in culturing γ δ -T cells, the injection of zoledronic acid into cancer patients can find that cancer cells express IPP in greater amounts, thereby increasing the sensitivity of γ δ -T cells to cancer cells. However, zoledronic acid is a drug for treating osteoporosis, and there is still a certain doubt about the use of zoledronic acid in culturing cells or injecting the zoledronic acid into patients, so that the development of a convenient, effective and safe culture medium for in vitro amplification and activation of gamma delta-T cells is still highly needed.
Disclosure of Invention
The invention provides a culture medium for in vitro amplification and activation of gamma delta-T cells, which comprises autologous dendritic cell exosomes with the concentration ranging from 5 mu g/ml to 50 mu g/ml. In a preferred embodiment, the concentration of the autologous dendritic cell exosomes is 25 μ g/ml.
In one embodiment, the medium further comprises interleukin-2; in a preferred embodiment, the concentration of the interleukin-2 is between 500IU/ml and 2000 IU/ml; in a more preferred embodiment, the concentration of IL-2 is 1000 IU/ml.
In one embodiment, the medium further comprises zoledronic acid; in a preferred embodiment, the concentration of the zoledronic acid is between 1 μ M and 20 μ M; in a more preferred embodiment, the concentration of zoledronic acid is 5 μ M.
In one embodiment, the culture medium further comprises autologous plasma, human AB serum, or fetal bovine serum; in a preferred embodiment, the autologous plasma, human AB serum or fetal bovine serum is about 10% of the total culture volume.
In one embodiment, the medium further comprises a basal medium; in a preferred embodiment, the basal medium is selected from the group consisting of AIM V, X-VIV015, CellGro SCGM, KBM 501, DMEM and RPM1-1640 medium.
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, the drawings show some, but not all alternative embodiments. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown. The accompanying drawings, which are incorporated in and constitute a part of this specification, help explain the principles of the invention.
Drawings
FIG. 1 is a gamma delta-T cell expansion fold analysis of the invention after addition of autologous dendritic cell exosomes to the culture medium.
FIG. 2 is an analysis of the poisoning efficiency of gamma delta T cells on Daudi cells after adding autologous dendritic cell exosomes to the culture medium according to the present invention.
FIG. 3 is the analysis of the poisoning efficiency of gamma delta T cells on A549 cells after adding autologous dendritic cell exosomes to the culture medium.
Detailed Description
In view of the above problems, the present invention provides a culture medium for in vitro amplification and activation of γ δ -T cells, which is added with autologous dendritic cell exosomes, and is capable of efficiently increasing the amplification factor of γ δ -T cells and producing γ δ -T cells with high cancer cytotoxic activity.
Definition of
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present document, including definitions, will control.
As used herein, "about," "approximately," or "approximately" shall generally mean within 20%, preferably within 10%, and more preferably within 5% of a particular value or range. As used herein, the terms "about", "approximately", or "approximately", unless expressly stated otherwise, are intended to be open-ended and are intended to encompass any number of degrees of certainty.
As used herein, the term "γ δ -T cell" refers to a cell surface antigen presenting CD3+And expressing TCR V gamma 9 and TCR V delta 2.
In the present invention, the "cell amplification factor" is determined in the following manner: "cell number after 12 days in vitro culture" was divided by "initial γ δ -T cell number isolated from peripheral blood mononuclear cells".
In the present invention, the "cancer cell killing efficiency" is obtained by performing a killing test using γ δ -T cells as effector cells (effector cells) and Daudi cell lines or a549 cell lines as target cells (target cells) at a ratio (E: T ratio) of the effector cells to the target cells of 0.5, 1 or 5, and using the ratio of the target cells to the effector cells as the killing efficiency.
In the present invention, an "exosome" is a minute membrane vesicle secreted by most cells, having a lipid bilayer membrane structure with a diameter of about 40-100 nm. Exosomes were first discovered in 1983, but it has been considered to be only a waste product of cells. Recently, however, it has been discovered that such minute membrane vesicles contain cell-specific proteins, lipids and nucleic acids, which can be transmitted to other cells as signaling molecules to alter the functions of other cells. Recent studies have found that exosomes play important roles in many physiopathologies, such as antigen presentation in immunity, tumor growth and migration, repair of tissue damage, etc., and that exosomes secreted by different cells have different compositions and functions.
Materials and methods
The peripheral blood sample is prepared by collecting whole blood from the arm of a subject according to a plan passed by the ethical committee, placing the whole blood in a sterile blood collection tube, and storing the whole blood at room temperature for subsequent treatment.
The basic culture medium used in the invention can be selected from: commercially available basal media such as CellGro SCGM (CellGenix corporation), KBM 501(Kohjin Bio corporation), AIM-V (Thermo Fisher corporation), X-VIV015(Lonza corporation), DMEM, RPM1-1640, and the like.
The medium of the present invention may contain suitable components such as proteins, cytokines, antibodies, serum, and compounds. The cytokine is sometimes interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), or interleukin-21 (IL-21).
Method for separating peripheral blood mononuclear cells from blood sample
7.5-8ml of blood was drawn into a blood collection tube containing anticoagulant heparin and Ficoll-Hypaque reagent, plus a polyester gel barrier to separate the two fluids. Separating blood collecting tube at 1800g at room temperatureHeart 20 min. After centrifugation is complete, plasma fractions are collected for subsequent cell culture and 5 to 10mm plasma layers are left on the interface, operating without disturbing the cell layer. Then, a Peripheral Blood Mononuclear Cell (PBMC) layer of the interface was collected by a pipette into a 15ml conical tube, the PBMC was washed with 10ml of Phosphate Buffered Saline (PBS) and the conical tube was inverted 5 times, and then centrifuged at 400g for 5 minutes. After repeating the washing step twice, the cells were resuspended in 5ml of PBS. Counting the number of cells, 1.3X10 can be isolated from 1ml of whole blood6The PBMC of (1). Finally, the proportion and the phenotype of the gamma delta-T cells in the PBMCs are confirmed by a flow cytometer.
Method for amplifying and activating gamma delta-T cells in vitro
After centrifugation of the peripheral blood mononuclear cell suspension in a 15ml conical tube at 400g for 5 minutes at room temperature, the supernatant was discarded. Cell culture medium was prepared by adding interleukin-2 (IL-2) and zoledronic acid (Zomet) to final concentrations of 1000IU/ml and 5. mu.M, respectively. Wherein zoledronic acid is added in liquid form, and 50. mu.l of zoledronic acid (concentration 4mg/5ml) is added per 30ml of the culture medium. The cell pellet was then resuspended in culture medium and adjusted to 1X10 per ml of culture medium6A cell. Using 24-well cell culture plates, add 1X10 per well6The cells are cultured. If large-scale culture is required, the culture medium can be 0.5x10 per square centimeter6The cell density was adjusted in accordance with the surface area of the culture dish or the culture flask used as a principle. Autologous plasma, human AB serum, fetal bovine serum, or autologous dendritic cell exosomes were then added to make up about 10% of the total culture volume (equivalent to a 24-well cell culture plate with 100 μ l cells per well). And (3) placing the cell culture plate in a cell culture box with the temperature of 37 ℃ and the content of 5% CO2 for culturing for 24-48 hours. Cell density was maintained at 0.5x10 per ml6~2x106Every 2 to 3 days, fresh medium containing 1000IU/ml interleukin-2 is added into each cell, and the cells are transferred to a new culture dish or a new culture bottle to be cultured according to the degree of cell expansion when necessary. Serum concentration in the medium was maintained at least at 1% during the culture. Cells were harvested on day 12 and run in flowThe number, phenotype and function of gamma delta-T cells were confirmed by the cytometer.
Analysis of cell surface antigens by flow cytometry
At 2x105Cells/200. mu.l the amplified and activated cells were placed in a 96-well plate, and 3. mu.l of a fluorescence-labeled antibody was added to react at 4 ℃ for 15 minutes, followed by washing 3 times with PBS, adding 400. mu.l of PBS to suspend the cells, and analyzing the fluorescence-labeling on the cell surface by flow cytometry. The fluorescence labeled antibody comprises anti-CD3 antibody, anti-TCR V gamma 9 antibody and anti-TCR V delta 2 antibody.
Gamma delta-T cell virus cancer cell killing capability test mode
The amplified and activated gamma delta-T cells are used as action cells (effector cells), and Daudi cell strains (lymph cancer cell strains) or A549 cell strains (lung cancer cell strains) are used as target cells (target cells). After the affected cells and the target cells were cultured in a mixed manner at 0.5:1, 1:1 or 5:1, they were reacted for 4 hours, and then the number of apoptotic cells was measured by staining with 7-AAD.
Preparation and purification of autologous dendritic cell exosomes
Autologous dendritic cell exosomes (Autologous dendritic cell exosomes) were prepared by replacing the dendritic cell culture medium cultured up to the fifth day with fresh cell culture medium, and adding Granulocyte-colony stimulating growth factor (GM-CSF) and interleukin-4 and continuing to culture the dendritic cells for 24 hours. The cultured medium was collected and centrifuged at 300g and 1000g for 10 minutes, respectively, followed by filtration through a filter having a pore size of 0.45 μm to remove cells and debris. The filtered medium was concentrated by centrifugation at 1000g for 45 minutes using a Centricon Plus-70 Millipore filter, then the dendritic cell exosomes were isolated from the medium by ultracentrifugation at 100,000g for one hour, washed twice with PBS, centrifuged at 1000g for 25 minutes through an Amicon Ultra-15 filter, and finally the dendritic cell exosomes were resuspended in 200. mu.L of PBS. Quantification of dendritic cell exosomes was performed using BCA protein assay kit (Thermo Scientific).
The amplified and activated gamma delta-T cells obtained by the method can be mixed with a proper excipient for storage, and the excipient can be a phosphate buffer solution, and finally, the pharmaceutical composition is prepared.
Examples
Example 1 culture results of addition of autologous dendritic cell exosomes to γ δ -T cell culture media
FIG. 1 is a graph showing the fold expansion analysis of γ δ -T cells after adding autologous dendritic cell exosomes to the culture medium. From FIG. 1, it was found that the cell expansion ratio was 6,236-fold at day 12 of culture using a medium containing 25. mu.l/ml of autologous dendritic cell exosomes; the control group (without autologous dendritic cell exosomes) had a 3,754 fold cell expansion.
Example 2 poisoning test of cultured γ δ -T cells of the present invention on Daudi cells
FIG. 2 is a graph showing the poisoning efficiency of γ δ -T cells on Daudi cells after adding autologous dendritic cell exosomes to the culture medium. From FIG. 2, it was found that the γ δ -T cell poisoning efficiency was 78.3% in the case of the E: T ratio of 5, when cultured using a medium containing 25 μ l/ml of autologous dendritic cell exosomes; the control group (without autologous dendritic cell exosomes) had a γ δ -T cell cytotoxic efficiency of 64.4%.
Example 3 poisoning test of cultured γ δ -T cells of the present invention on a549 cells
FIG. 3 is the analysis of the poisoning efficiency of gamma delta T cells on A549 cells after adding autologous dendritic cell exosomes to the culture medium. From FIG. 3, it was found that γ δ -T cell poisoning efficiency was 58.9% in the case of the E: T ratio of 5 and addition of zoledronic acid, cultured using the medium containing 25 μ l/ml of autologous dendritic cell exosomes; the control group (without autologous dendritic cell exosomes) had a γ δ -T cell cytotoxic efficiency of 43.7%.
In conclusion, the autologous dendritic cell exosomes are added into the gamma delta-T cell culture medium, so that the amplification rate of the gamma delta-T cells and the poisoning activity on Daudi and A549 cancer cells can be effectively improved.
The foregoing description of the embodiments of the present invention has been presented for purposes of illustration and description, and is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Modifications or variations are possible in light of the above teachings.
Alternatives to the embodiments will be apparent to those skilled in the art without departing from the spirit and scope of the invention. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description and examples. Some references, which may include patents, patent applications, and various publications, are cited and discussed herein. All references cited and discussed in this specification are incorporated herein by reference in their entirety as if each had been individually incorporated for the same degree of completeness.
Claims (10)
1. A culture medium for in vitro expansion and activation of γ δ -T cells comprising autologous dendritic cell exosomes at a concentration ranging from 5 μ g/ml to 50 μ g/ml.
2. The culture medium according to claim 1, wherein the concentration of autologous dendritic cell exosomes is 25 μ g/ml.
3. The culture medium of claim 1, further comprising interleukin-2.
4. The culture medium of claim 3, wherein the concentration of interleukin-2 is between 500IU/ml and 2000 IU/ml.
5. The culture medium of claim 4, wherein the concentration of interleukin-2 is 1000 IU/ml.
6. The culture medium of claim 1, further comprising zoledronic acid.
7. The culture medium of claim 6, wherein the concentration of zoledronic acid is between 1 μ M and 20 μ M.
8. The culture medium of claim 7, wherein the concentration of zoledronic acid is 5 μ M.
9. The culture medium of claim 1, further comprising autologous plasma, human AB serum, or fetal bovine serum, wherein the autologous plasma, human AB serum, or fetal bovine serum is about 10% of the total culture volume.
10. The culture medium according to any one of claims 1 to 9, further comprising a basal medium; wherein the basal medium is selected from the group consisting of AIM V, X-VIV015, CellGro SCGM, KBM 501, DMEM and RPM1-1640 medium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962877849P | 2019-07-24 | 2019-07-24 | |
US62/877,849 | 2019-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112300990A true CN112300990A (en) | 2021-02-02 |
Family
ID=74336340
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010475465.8A Pending CN112300989A (en) | 2019-07-24 | 2020-05-29 | Method for in vitro amplification and activation of gamma delta-T cells |
CN202211403552.8A Pending CN115678847A (en) | 2019-07-24 | 2020-05-29 | Method for in vitro amplification and activation of gamma delta-T cells |
CN202010475488.9A Pending CN112300990A (en) | 2019-07-24 | 2020-05-29 | Culture medium for in-vitro amplification and activation of gamma delta-T cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010475465.8A Pending CN112300989A (en) | 2019-07-24 | 2020-05-29 | Method for in vitro amplification and activation of gamma delta-T cells |
CN202211403552.8A Pending CN115678847A (en) | 2019-07-24 | 2020-05-29 | Method for in vitro amplification and activation of gamma delta-T cells |
Country Status (2)
Country | Link |
---|---|
CN (3) | CN112300989A (en) |
TW (2) | TWI768357B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024103125A1 (en) * | 2022-11-18 | 2024-05-23 | Royal Melbourne Institute Of Technology | Method of modifying cells |
TWI840269B (en) * | 2023-07-06 | 2024-04-21 | 浩河未來實業有限公司 | Exosome manufacturing system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108103026A (en) * | 2017-12-05 | 2018-06-01 | 四川省肿瘤医院 | γ δ-T cell excretion body for immunotherapy of tumors and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105112370B (en) * | 2015-08-25 | 2019-02-05 | 杭州优善生物科技有限公司 | A kind of method and its application of stimulated in vitro peripheral blood gamma delta T cells high efficiently multiplying |
CN106399241B (en) * | 2016-09-09 | 2019-06-04 | 安徽省立医院 | The culture medium and method of amplification in vitro gamma delta T cells |
DE102017127984B4 (en) * | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Method for the propagation and activation of γδ T cells |
-
2020
- 2020-05-29 TW TW109118019A patent/TWI768357B/en active
- 2020-05-29 CN CN202010475465.8A patent/CN112300989A/en active Pending
- 2020-05-29 TW TW109118018A patent/TWI768356B/en active
- 2020-05-29 CN CN202211403552.8A patent/CN115678847A/en active Pending
- 2020-05-29 CN CN202010475488.9A patent/CN112300990A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108103026A (en) * | 2017-12-05 | 2018-06-01 | 四川省肿瘤医院 | γ δ-T cell excretion body for immunotherapy of tumors and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
KATHERINE E.KUNIGELIS ET AL.: "The dichotomy of tumor exosomes(TEX) in cancer immunity: is it all in the conTEXt?", 《VACCINES(BASEL)》 * |
NAOHIRO SEO ET AL.: "Exosome-mediated regulation of tumor immunology", 《CANCER SCI》 * |
冯奇等: "树突状相关外泌体在肿瘤中的研究进展", 《临床与病理杂志》 * |
吴振勇等: "一种gamma-delta T细胞体外扩增体系的研制", 《临床医学工程》 * |
Also Published As
Publication number | Publication date |
---|---|
CN115678847A (en) | 2023-02-03 |
TW202104578A (en) | 2021-02-01 |
TWI768357B (en) | 2022-06-21 |
CN112300989A (en) | 2021-02-02 |
TWI768356B (en) | 2022-06-21 |
TW202118858A (en) | 2021-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190071640A1 (en) | Methods and materials for the generation of regulatory t cells | |
CN108588022B (en) | Method for enriching human CD4+ and CD8+ TCM cells through in vitro culture | |
Lenshof et al. | Efficient purification of CD4+ lymphocytes from peripheral blood progenitor cell products using affinity bead acoustophoresis | |
CN112251406B (en) | Exosome sorting method in NK cell activation stage | |
Hasebe et al. | Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses | |
TWI768356B (en) | A culture medium for in vitro expansion and activation of gamma delta t cells | |
CN111918963A (en) | CD3 negative cell population expressing chemokine receptor and cell adhesion molecule and its use and preparation method | |
WO2015014291A1 (en) | Lymph cell amplification and activation method via serum-free cultivation | |
JP2014030375A (en) | Method for obtaining monocytes or nk cells | |
CN115521914A (en) | Human primary natural killer cell in-vitro amplification system and method | |
Dolgova et al. | Nonadherent spheres with multiple myeloma surface markers contain cells that contribute to sphere formation and are capable of internalizing extracellular double-stranded DNA | |
CN116426475B (en) | NK cell in-vitro activation and amplification method | |
JP2009195228A (en) | Method for producing controllable t cell and apparatus for amplifying controllable t cell | |
KR20130103485A (en) | Cells expressing th1 characteristics and cytolytic properties | |
Tian et al. | Non-invasive T cells adoptive immunotherapy for solid tumor with gel anti-tumor T-cell injections | |
CN108486055B (en) | Culture medium and application thereof in central memory type T lymphocyte culture | |
CN110628714B (en) | Serum-free cell culture solution for in vitro amplification of natural killer cells and natural killer T cells | |
TWI669400B (en) | A serum-free cell culture medium for in-vitro expansion of nature killer cells and nature killer t cells | |
EP3962604A1 (en) | Systems and methods for modulating a cell phenotype | |
KR101499345B1 (en) | Medium for ex vivo amplification of canine natural killer cell and ex vivo culture method of canine natural killer cell using the same | |
CN110628715B (en) | Method for in vitro amplification of natural killer cells and natural killer T cells and pharmaceutical composition thereof | |
Gunn | Novel Biopolymers for the Activation and Expansion of T-cells: Towards 3D Scaffolds for Cell Therapy | |
CN114958740A (en) | Method for in vitro culture and enrichment of human NK cells | |
Bressler et al. | Sequential appearance of basophils and mast cells from human bone marrow in long-term suspension culture | |
TW202000900A (en) | A method for in-vitro expansion of nature killer cells (nk cells) and nature killer t cells (nkt cell) and the pharmaceutical composition thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210202 |
|
RJ01 | Rejection of invention patent application after publication |